At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
Lisocabtagene maraleucel demonstrated potential improved patient outcomes compared with mosunetuzumab for patients with R/R FL who have had 2 or more lines of prior therapy, according to an unanchored matching-adjusted indirect comparison.
Lisocabtagene maraleucel demonstrated potential improved patient outcomes compared with mosunetuzumab for patients with R/R FL who have had 2 or more lines of prior therapy, according to an unanchored matching-adjusted indirect comparison.
According to results from a real-world retrospective analysis, dasatinib and nilotinib demonstrate comparable efficacy and tolerability among patients with chronic myeloid leukemia in chronic phase.
According to results from a real-world retrospective analysis, dasatinib and nilotinib demonstrate comparable efficacy and tolerability among patients with chronic myeloid leukemia in chronic phase.
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Following CAR-T therapy relapse, study findings suggest the timing of bispecific antibody treatment administration may be associated with improved responses among patients with B-cell lymphomas.
Following CAR-T therapy relapse, study findings suggest the timing of bispecific antibody treatment administration may be associated with improved responses among patients with B-cell lymphomas.
For patients with chronic myeloid leukemia in chronic phase previously treated with tyrosine kinase inhibitors, asciminib demonstrated efficacy and tolerability in a real-world setting.
For patients with chronic myeloid leukemia in chronic phase previously treated with tyrosine kinase inhibitors, asciminib demonstrated efficacy and tolerability in a real-world setting.
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
A recent phase 3 trial evaluating the use of denileukin diftitox-CXDL for relapsed/refractory cutaneous T-cell lymphoma demonstrated reduced skin tumor burden and promising tolerability.
A recent phase 3 trial evaluating the use of denileukin diftitox-CXDL for relapsed/refractory cutaneous T-cell lymphoma demonstrated reduced skin tumor burden and promising tolerability.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
